Navigation Links
Thoratec Reports First Quarter 2012 Results
Date:5/1/2012

ental revenues recorded as a result of the Levitronix Medical acquisition completed during the third quarter of 2011. The Thoratec® product line, which includes the PVAD and IVAD, accounted for revenues of $5.8 million compared to revenues of $7.3 million a year ago. In the first quarter of 2012, pump sales accounted for $92.6 million compared to sales of $70.8 million a year ago.  Non-pump sales were $33.6 million versus sales of $28.2 million in the first quarter of 2011. The balance of the company's revenues reflects contributions from its graft business. Revenues in the U.S. were $103.9 million versus revenues of $82.5 million a year ago. International revenues in the first quarter of 2012 were $22.9 million versus revenues of $17.0 million a year ago. Foreign exchange rate fluctuations had a negative impact of $0.5 million in the first quarter of 2012 compared to the first quarter of 2011.

GAAP gross margin in the first quarter of 2012 was 69.3 percent versus 68.1 percent a year ago. Non-GAAP gross margin, which is described later in this press release, was 71.6 percent versus 70.5 percent a year ago. The year-over-year increase in gross margin was due to volume-based efficiencies and the contribution from the acquisition of Levitronix Medical.Operating expenses on a GAAP basis in the first quarter of 2012 were $50.9 million versus $40.7 million a year ago. On a non-GAAP basis, operating expenses were $45.7 million in the first quarter of 2012 versus $36.8 million a year ago. Non-GAAP operating expenses are described later in this press release.
The year-over-year increase in operating expenses was due primarily to spending on product and market development initiatives, including sales force expansion and the addition of research and development personnel, and the inclusion of Levitronix Medical.

On a GAAP basis, other income was $0.7 million in the first quarter of 2012 versus other expense of $2.1 million in the prior year. On
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Thoratec Schedules First Quarter Conference Call, Webcast
2. Thoratec Comments on February 23rd Voluntary Medical Device Correction Notification
3. Thoratec Presentation at Leerink Swann Healthcare Conference to be Webcast
4. Thoratec Schedules Fourth Quarter Conference Call, Webcast
5. Thoratec Announces Appointment of William A. Hawkins to Board of Directors
6. Thoratec Presentation at Oppenheimer Conference to Be Webcast
7. Thoratec Corporation Authorizes Additional $50 Million Share Repurchase Program
8. Thoratec Reports Third Quarter Fiscal 2011 Results
9. Thoratec Schedules Third Quarter Conference Call, Webcast
10. Thoratec Presentation at Lazard Capital Markets Circulatory Assist Device Day to be Webcast
11. Thoratec Announces Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 ... has been commenced in the United States District Court ... on behalf of investors who purchased Galectin Therapeutics Inc. ... 6, 2014 and July 28, 2014. For ... The complaint alleges that during the Class Period the ...
(Date:8/28/2014)...   Edison Nation Medical , the premier ... for product ideas to improve the health and ... through the 6-month search ( www.EdisonNationMedical.com/Seniors ) will ... healthcare retailers with whom Edison Nation Medical has ... 65 and older. The objective of ...
(Date:8/28/2014)...  Seres Health, a clinical-stage therapeutics company developing ... microbiome, announced today that Dr. David Cook ... Chief Scientific Officer, will be presenting at the ... (ICAAC). The presentation will highlight the scientific and ... bacterial spores derived from the human microbiome, and ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2
... CRAIGAVON, Northern Ireland , August 2, 2010 ... a range of solutions,specifically designed to meet the needs of the ... , ... biopharma companies in adopting,biomarker strategies to enable them to better understand ...
... Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today that ... Healthcare Conference on Thursday, August 5, 2010 at 1:15 ... held at the Sheraton New York Hotel & Towers.  Steve Worland, Ph.D., ... Anadys and its clinical development programs. , ...
Cached Medicine Technology:Almac Launch Biomarkers for Biopharma 2Almac Launch Biomarkers for Biopharma 3Anadys Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference 2
(Date:8/28/2014)... 28, 2014 The Governor of Yucatán, ... at a press conference; this event is organized ... Ministry of Economy through the National Microenterprise Financing Program ... 2nd to the 5th at the Convention Center Yucatan ... is a great responsibility for Yucatan to host the ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for ... new world’s record by walking 5,000 miles in a single ... amazed by the thousands of individual stories of TrekDesk treadmill ... stand out more than the others. , Kirklyn has launched ... which tallies a range of 54,823 steps (presumably on an ...
(Date:8/28/2014)... Bank lending to the private sector in the ... in real terms, and continuing to fall behind the rest ... the international accountancy network. , UHY warns that the figures ... credit crunch lingers on. , UHY says in the US, ... been wiped out by inflation. Over the four years since ...
(Date:8/28/2014)... sleep not only puts teens at risk for poor grades, ... warn. The study authors analyzed data collected from more ... Nearly one-fifth of them got less than six hours of ... group was 20 percent more likely to be obese at ... of sleep per night at age 16, the investigators found. ...
(Date:8/28/2014)... the earliest birds take wing? Did they fall from trees ... did they run along the ground and pump their "arms" ... years in the past, but a new University of California, ... have an innate ability to maneuver in midair, a talent ... than fall from a perch. , The study looked at ...
Breaking Medicine News(10 mins):Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3
... Annual JMP Securities Research Conference ... on May 21 - ... Meeting on May 22 -, SAN DIEGO, May 14 Ardea Biosciences, Inc.,(Nasdaq: ... Annual Research Conference. Additionally, Ardea will be,hosting a live webcast and conference call of ...
... 14 Biotel Inc. (OTC Bulletin,Board: BTEL) announced results ... earnings of $99,000, or $0.03 per diluted share, on ... or $0.07 per diluted,share, on revenues of $2,990,000 for ... ended March 31, 2008, Biotel had net earnings of ...
... Patients more likely to survive using chemoradiation, and new ... -- Tonsil and tongue cancers linked to human papillomavirus ... treatments, while those that express high levels of a ... most deadly, a new study concludes. , University of ...
... other treatments work well, too, giving patients options , , WEDNESDAY, ... kind supports the use of a popular three-drug regimen for ... drugs is a good alternative. , But an older ... Sharon Riddler, assistant professor of medicine at the University of ...
... , , WEDNESDAY, May 14 (HealthDay News) -- A bundle of ... cardiovascular disease in a study of older Swedish men, researchers ... long process that might one day lead to widespread medical ... such as high blood pressure and cholesterol, said Dr. Johan ...
... Honored for Their Research -, PALO ALTO, ... Ph.D. students and two professors with the company,s ... field of organic,chemistry. The winners participated in Roche,s ... on the important role of organic,chemistry in pharmaceutical ...
Cached Medicine News:Health News:Ardea Biosciences Announces Upcoming Corporate Meetings 2Health News:Ardea Biosciences Announces Upcoming Corporate Meetings 3Health News:Biotel Announces Profitable Third Quarter Ended March 31, 2008 2Health News:HPV Tied to Better Tongue, Tonsil Cancer Outcomes 2Health News:Study Supports Popular HIV Drug Regimen 2Health News:Study Supports Popular HIV Drug Regimen 3Health News:Biomarkers Predict Heart Deaths 2Health News:Biomarkers Predict Heart Deaths 3Health News:Roche Symposium Showcases Accomplishments of Next Generation of Chemists 2Health News:Roche Symposium Showcases Accomplishments of Next Generation of Chemists 3
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ... and by enzymatic conversion of DHEA in ... major C19 steroid secreted by the adrenal ... and estrogen biosynthesis. DHEA possesses relatively weak ...
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Medicine Products: